Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Outcomes Research

Background:

• Cardiogenic shock complicating acute myocardial infarction (MI) is a leading cause of hospital mortality.
• Percutaneous coronary intervention (PCI) is a critical treatment for acute MI.
• Outcomes for PCI in cardiogenic shock have evolved with technological advancements.

Purpose of the Study:

• To compare patient characteristics and outcomes of PCI for cardiogenic shock complicating MI before and after the widespread adoption of stents.
• To evaluate the impact of stent use and adjunctive therapies on acute success and survival rates.

Main Methods:

• Retrospective observational review of 93 consecutive patients undergoing PCI for cardiogenic shock complicating MI.
• Comparison of two cohorts: pre-stent era (n=44) and stent era (n=49) over a 15-year period (1988-2003).
• Analysis included patient characteristics, procedural success, in-hospital survival, and long-term survival using Kaplan-Meier curves and logistic regression.

Main Results:

• Patients in the stent era had comparable coronary disease extent but more ST-elevation MI and comorbidities.
• PCI in the stent era demonstrated higher rates of acute procedural success and improved in-hospital survival.
• Highly significant improvement in overall survival (P < 0.0001) was observed in the stent era.
• Stent use, combined with glycoprotein IIb/IIIa inhibitors and dual-antiplatelet therapy, was significantly associated with improved survival (P = 0.007).

Conclusions:

• PCI in the stent era, utilizing stents and modern adjunctive therapies, significantly improves acute success and survival for patients with cardiogenic shock complicating acute MI.
• Advancements in interventional techniques and pharmacotherapy have markedly improved the prognosis for this high-risk patient population.